F102 A Primer and Practical Approach to Cancer Checkpoint Inhibitors for the Dermatologist
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Novel cancer immunotherapies, specifically immune checkpoint inhibitors (CPIs), have recently emerged, redefining treatment paradigms in oncology. However, CPIs present significant complications, with pruritus and skin-related toxicities being among the most common adverse effects. These issues necessitate a new skill set for practitioners caring for cancer patients receiving this class of medication. This session aims to enhance dermatology practitioners' knowledge of the underlying science of cancer immunotherapies, common adverse events and skin-related toxicities, and current NCCN guidelines alongside other management strategies for CPI-induced adverse events.
LEARNING OBJECTIVES
Summarize the science of the novel cancer immunotherapies called checkpoint inhibitors and their mechanisms of actions.
Discuss the current FDA-approved checkpoint inhibitor therapies and their uses in dermatology along with associated adverse events and dermatology-related toxicities.
Apply the NCCN guideline recommendations for the management of checkpoint inhibitor-related skin toxicities.
SCHEDULE
7:30 PM
Introduction and Overview of FDA-Approved Checkpoint Inhibitors with a Focus on NCCN Guideline Skin Cancer Indications
Oliver J. Wisco, DO, FAAD
7:40 PM
Q&A with Dr. Wisco
Oliver J. Wisco, DO, FAAD
7:45 PM
Overview of the Science of Cancer Checkpoint Inhibitors and the Mechanism of Action for Each Class
Jason Ezra Hawkes, MD, MS, FAAD
8:00 PM
Q&A with Dr. Hawkes
Jason Ezra Hawkes, MD, MS, FAAD
8:05 PM
Dermatologic Checkpoint Inhibitor Neoadjuvant Use
Michael Tetzlaff, MD, PhD
8:20 PM
Q&A with Dr. Tetzlaff
Michael Tetzlaff, MD, PhD
8:25 PM
Checkpoint Inhibitor Toxicity Incidence Overall and Correlation with Response with Concerns in Patients with Pre-Existing Skin Disease
Noah Io Hornick, MD, PhD, FAAD
8:40 PM
Q&A with Dr. Hornick
Noah Io Hornick, MD, PhD, FAAD
8:45 PM
Review of NCCN guidelines for Managing Checkpoint Inhibitor ADRs and Dermatology-Related Toxicities
Jennifer N. Choi, MD, FAAD
9:00 PM
Q&A with Dr. Choi
Jennifer N. Choi, MD, FAAD
9:05 PM
Case Discussions on Cutaneous Oncology Cases and Management of Checkpoint Inhibitor induced Dermatologic Toxicities
SPEAKERS
Jennifer N. Choi, MD, FAAD
Jason Ezra Hawkes, MD, MS, FAAD
Noah Io Hornick, MD, PhD, FAAD
Michael Tetzlaff, MD, PhD
Oliver J. Wisco, DO, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Jennifer N. Choi, MD, FAAD
Azitra, Inc – Advisory Board(Fees); CeraVe/Valeante – Independent Contractor(Fees); Incyte Corporation – Investigator(Grants/Research Funding); Janssen Global Services, LLC – Advisory Board(Fees); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Fees); OnQuality Pharmaceuticals, Ltd. – Advisory Board(Fees); Parexel – Data Safety Monitoring Board(Fees); PraHealth Sciences – Advisory Board(Fees); Regeneron Pharmaceuticals, Inc. – Data Safety Monitoring Board(Fees);
Jason Ezra Hawkes, MD, MS, FAAD
AbbVie – Advisory Board(Fees), Investigator(Grants/Research Funding); Acelyrin – Investigator(Grants/Research Funding); Alumis – Investigator(Grants/Research Funding); Amgen – Investigator(Grants/Research Funding); Apogee Therapeutics – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Arcutis, Inc. – Advisory Board(Fees); Blueprint Medicines – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Boehringer Ingelheim – Advisory Board(Fees), Speaker(Honoraria); Bristol-Myers Squibb – Advisory Board(Honoraria), Speaker(Honoraria); Celldex – Investigator(Grants/Research Funding); Concert Pharmaceuticals – Investigator(Grants/Research Funding); Dermavant Sciences, Inc. – Advisory Board(Honoraria); Eli Lilly and Company – Advisory Board(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria); Galderma – Advisory Board(Honoraria), Speaker(Honoraria); Incyte Corporation – Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); LEO Laboratories Ltd (LEO Pharma) – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Novartis – Advisory Board(Fees), Speaker/Faculty Education(Honoraria); Oruka Therapeutics – Investigator(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Speaker(Honoraria), Stockholder(Stock); Sanofi Genzyme – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Speaker(Honoraria);
Noah Io Hornick, MD, PhD, FAAD
Shook Hardy & Bacon – Consultant (1099 relationship)(Fees); Therakos, Inc. – Data Safety Monitoring Board(Fees);
Michael Tetzlaff, MD, PhD
No financial relationships exist with ineligible companies.
Oliver J. Wisco, DO, FAAD
Castle Biosciences – Investigator(Fees); Regeneron – Consultant (1099 relationship)(Fees), Investigator(Fees);